RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether giving triptorelin and radiation therapy soon after surgery or later after surgery is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying giving triptorelin and radiation therapy soon after surgery to see how well it works compared with giving them later after surgery in treating patients who have undergone surgery for intermediate-risk stage III or stage IV prostate cancer.

Brief Title

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Official Title

Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk.

Brief Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such <br /> as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses <br /> high-energy x-rays to kill tumor cells. It is not yet known whether giving triptorelin and <br /> radiation therapy soon after surgery or later after surgery is more effective in treating <br /> prostate cancer. <br /> <br /> PURPOSE: This randomized phase III trial is studying giving triptorelin and radiation therapy <br /> soon after surgery to see how well it works compared with giving them later after surgery in <br /> treating patients who have undergone surgery for intermediate-risk stage III or stage IV <br /> prostate cancer.

Detailed Description

OBJECTIVES:

Primary

- Compare the efficacy, in terms of event-free survival at 5 years, of immediate
radio-hormonal therapy immediately after prostatectomy for tumor pT2, R1, pN0, or pNx
versus radio-hormonal therapy at biochemical relapse.

Secondary

- Compare the overall survival of patients treated with these regimens.

- Compare the metastasis-free survival of these patients.

- Compare the acute and late toxicities of these regimens in these patients.

- Compare the quality of life of patients treated with these regimens.

- Compare the functional dependence of patients over 75 years old.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

- Arm I (delayed treatment): Patients receive triptorelin intramuscularly on day 1 and
then 3 months later. Patients also undergo conformal radiotherapy daily, 5 days a week,
for 7 weeks. Treatment begins at biochemical relapse (PSA is more than 0.2 ng/mL) and
before PSA is more than 2 ng/mL.

- Arm II (immediate treatment): Patients receive treatment as in arm I, but treatment
begins within 6 months after surgery.

After completion of study treatment, patients are followed for up to 5 years.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.

Inclusion criteria:

  1. Patient must have undergone curative surgery for a localized adenocarcinoma of the
     prostate

  2. pT3a, pT3b (or pT4 by reaching the bladder neck), or R1 disease (stage III or IV)

  3. PSA ≤0.1 ng/mL after prostatectomy (confirmed at 1 month)

  4. May receive treatment within 6 months after surgery

  5. Positive margins (tumoral glands in contact with contour ink) on the surgical specimen

  6. pN0 or pNx (lymph nodes resected during negative prostatectomy or lymph nodes not
     resected)

  7. No current clinical or biochemical progressive disease

  8. Life expectancy ≥10 years

  9. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

 10. Patient must be affiliated to the social security system

 11. Patient must have received the information sheet and signed the consent form

Exclusion criteria:

  1. Patient with prostate cancer other than adenocarcinoma

  2. Gleason score ≥8 and with seminal vesicles involved

  3. pN1 disease (Histologically confirmed nodal invasion during initial lymph node
     resection)

  4. pT2 disease

  5. Prior surgical or chemical castration

  6. Prior hormonal therapy

  7. Prior radiotherapy within 3 months after radical prostatectomy

  8. Prior pelvic radiotherapy

  9. No history of cancer (except basal cell skin cancer) within 5 years of surgery

 10. No known severe hypertension uncontrolled by appropriate therapy (≥160 mm Hg systolic
     and/or ≥90 mm Hg diastolic)

 11. Known hypersensitivity to gonadotropin-releasing hormone or its analogs

 12. Contraindication to intramuscular injection

 13. Concurrent participation in another interventional study

 14. Patients under protective custody or guardianship, unable to comply with the specific
     requirements of the study or unable to understand the purpose of the study